# 2025-16269: YORVIPATH Drug Scores FDA Patent Review Extension

2025-16269, Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16269
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16269
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41578
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

YORVIPATH Drug Scores FDA Patent Review Extension

## Summary

The FDA has officially set the review period for YORVIPATH, a human drug product, so its patent can be extended. This means the company behind YORVIPATH gets more time to protect their invention and keep competitors at bay. If you’re in the drug business, watch for these updates—they can affect when new versions hit the market and how long the original maker stays in charge.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YORVIPATH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claim that human drug product.

## Effects PRIA read

- FDA OKs Patent-Extension Review For YORVIPATH: benefit, medium. The FDA has determined the regulatory review period for YORVIPATH so the drug’s maker can seek a patent extension from the U.S. Patent and Trademark Office. This gives the company extra time to protect its invention and can keep competitors from selling the same drug while the extension is in effec…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16269 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16269/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yorvipath)
- [2025-16269 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16269.pdf)

## Related
- [Previous: 2025-16268, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2025-16268)
- [Next: 2025-16270, Determination of Regulatory Review Period for Purposes of Patent Extension; ZUN…](https://policyrisk.com/federal-register/2025-16270)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16269 (as of 2026-06-08).
